Since 1995, when the FDA approved riluzole for amyotrophic lateral sclerosis (ALS) โ offering a median survival extension measured in weeks โ more than 60 compounds have advanced to clinical evaluation, with the overwhelming majority failing to demonstrate efficacy.(p1) It is worth distinguishing, within that graveyard, between uninformative โfailedโ trials that lacked biomarkers and left […]
Posted in Featured, Neuroplasticity, Pharma and Medical Device, Regulatory Medical Writing 
Comments Off on ๐๐ก๐ ๐๐๐ ๐๐ซ๐ฎ๐ ๐ ๐ซ๐๐ฏ๐๐ฒ๐๐ซ๐ ๐ข๐ฌ ๐๐ซ๐จ๐ฐ๐๐๐
The choroid plexus (ChP): hydrodynamic bottleneck and ground zero for Alzheimer’s diseaseย https://ejournals.uni-muenster.de/fnp/article/view/9368/9664 The Institute has advanced a Dual Sequestration Hypothesis (DSH) related to the protein signatures prevalent in Alzheimer’s disease.ย If the DSH is correct, the ChP should enlarge and become the sentinel hydrodynamic bottleneck as synthetic particles and their protein sequestrants accumulate. This […]
Posted in Featured, Neuroplasticity, Pharma and Medical Device Comments Off on The choroid plexus (ChP): hydrodynamic bottleneck and ground zero for Alzheimer’s
https://doi.org/10.1016/j.drudis.2026.104678ย Free download of the article using this link until June 16:ย https://authors.elsevier.com/a/1n0uP4r9Rkz1l6 Highlights New four-pillar framework accelerates deorphanization of dark GPCR targets. (77 chars) GPR149 structural analysis identifies non-canonical ERY and DPxxF motifs. (76 chars) Path-agnostic screening bypasses traditional Gi/oย signaling limitations. (75 chars) Integrated CNS and metabolic mapping reveals GPR149โฒs dual-domain value. (76 chars) […]
Posted in About, Featured, Neuroplasticity Comments Off on Accelerating the Orphan GPCR Pipeline: GPR149 as a Case Study in Dual-Domain Target Validation
In the 1950s, my physicist father, Eugene Guth, met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory. Einstein, it turned out, was more interested in the philosophy of physics than the math, a topic equally of interest to my dad.ย See https://michaelguth.com/family/HistoryofPhysicsbyEugeneGuth.htm Mathematics and philosophy of physics have relevance […]
Posted in About, Featured, Neuroplasticity, Pharma and Medical Device Comments Off on In the 1950s, my physicist father met with Albert Einstein at the Institute for Advanced Study to discuss unified field theory.
New evidence provides a stronger link between chronic anxiety and future neurocognitive decline, demanding a re-evaluation of how we approach dementia prevention in clinical practice. A major updated meta-analysis, now available in the Journal of Clinical Medicine, confirms that anxiety is significantly associated with an increased risk of all-cause dementia. This extensive study, spanning nine […]
Posted in Featured, Neuroplasticity, Regulatory Medical Writing Comments Off on Authority, Long-term Reach, and “Save” Signals
๐๐๐๐๐ฅ๐ข๐ง๐: ๐๐ก๐ “๐๐ก๐๐ฉ๐” ๐จ๐ ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง: ๐๐ก๐ฒ ๐๐จ๐ซ๐ฉ๐ก๐จ๐ฅ๐จ๐ ๐ข๐๐๐ฅ ๐๐๐ซ๐ค๐๐ซ๐ฌ ๐๐ซ๐ ๐ญ๐ก๐ ๐ ๐ฎ๐ญ๐ฎ๐ซ๐ ๐จ๐ ๐๐๐ ๐ข๐ง ๐๐๐ In the high-stakes world of CNS drug discovery and Real-World Evidence (RWE), weโve leaned on behavioral scales for too long. But in 2026, the data is clear: Morphological Biomarkers are the new gold standard. Recent advancements in Geometric Morphometrics prove […]
Posted in Featured, Neuroplasticity Comments Off on ๐๐ก๐ “๐๐ก๐๐ฉ๐” ๐จ๐ ๐๐ง๐ง๐จ๐ฏ๐๐ญ๐ข๐จ๐ง: ๐๐ก๐ฒ ๐๐จ๐ซ๐ฉ๐ก๐จ๐ฅ๐จ๐ ๐ข๐๐๐ฅ ๐๐๐ซ๐ค๐๐ซ๐ฌ ๐๐ซ๐ ๐ญ๐ก๐ ๐
๐ฎ๐ญ๐ฎ๐ซ๐ ๐จ๐ ๐๐๐ ๐ข๐ง ๐๐๐
Beyond the BBB: Mapping the 2026 Milestone Year for Neuroscience.ย As we move through Q1, all eyes in the neuroscience community are on April 5, 2026โthe PDUFA target action date for tividenofusp alfa (DNL310). If approved, tividenofusp alfa will be a watershed moment: the first commercial validation of a Transport Vehicle (TV) enabled enzyme replacement […]
Posted in Featured, Regulatory Medical Writing Comments Off on Beyond the BBB: Mapping the 2026 Milestone Year for Neuroscience
Is the Next Breakthrough in “Chemo Brain” Treatment Hiding in Diabetes Research? For cancer survivors, the battle often doesn’t end with remission. Chemotherapy-Induced Cognitive Impairment (CICI)โwidely known as “Chemo Brain”โremains one of the most debilitating long-term side effects of treatment, affecting memory, executive function, and attention. While the clinical impact is well-documented, therapeutic options remain […]
Posted in Featured, Neuroplasticity, Pharma and Medical Device Comments Off on “Chemo Brain” and Diabetes Research
Image:ย Computerย Simulation of SARS-CoV-2. Reprinted with kind permission of Janet Iwasa of http://animationlab.utah.edu/cova Should I Get a COVID-19 Vaccine in December 2025 or January 2026? As we move through the winter of 2025-2026, the question of whether to get a COVID-19 vaccine is highly relevant, especially as respiratory viruses typically peak during this time. The […]
Posted in Featured, Pharma and Medical Device 
Tags: AHCC, Calcifediol study, CASIRIVIMAB, Coronavirus, COVID-19, IMDEVIMAB, Interferon, Melatonin, SHADE study, Vitamin D Comments Off on COVID-19 Treatment Strategies: Dec 2025 update
And we already know how small a role the cancer gene plays in the onset of cancer: there has been an 8-fold to 17-fold increase in the incidence of cancer in the last hundred years, but not even one-millionth of 1 percent of that increase can be related to genes.
Genes evolve over hundreds of thousands (if not millions) of years, which means that the so-called cancer gene has had no impact on the huge increase weโve seen since 1900. Virtually 90 percent of the cancer that we see today cannot possibly have anything to do with genes.
Posted in Featured Tags: Cancer, cancer stem cells, first cell Comments Off on The State of Cancer Research